fda1afae8014da8b8d284b0e21327ad4:8fa3a37a6a3bbf3cd646330065758666f894d9a84c550d6bde27321c36dd50fd446912260a403a73ff8b6eda7e0a7ce1fe975dd98ce0f77b5961a73b5a265934500cb7c5f0efd904f1411800093f07a90f1e6c446c27eaa7ae5e7487ce1b957a901d0f410b905d4758a16838c8a940b34ae364c17795d0655764ce57d7ed7689d6e5379dc84a8773e1c58cf5a4b042e47c212b559624e550b21b39fdc9a24beeb390c4006625ad62293f7da3ee1d402002d16ff9bcfe6234cd7293a1b72d90b95274738f8a75e837710c569798bb812d24490447b268d7984d41f936b6579eb5b2f23d83c87382b560da9444b8d853c725333375ed07b4b95b532714ed9c009648ddc47eca0fcea61e59dc72bc6adcd497de93adcb7d5526167f7336cfa5a0afca74448bc5cff69e0d808585f9815db2a6d07bf36de0ec2f053bbebf4218ab0a335effe79e7404dfc286eb7cd874ccfa9adb88c80edc1c096007a87daea29451b63087f6a0a6308137b39e613d7deb2350258eac9a08911a31e8223cdee0372bbd1f91b75007c91feafa208625eadc0ed154660e9a1b9d0f192a5de5a4df59e75fe08877d634584c